104PAugmentation of NAD+ levels by enzymatic action of NAD(P)H quinone oxidoreductase 1 attenuates adriamycin-induced cardiomyopathy

Background: Adriamycin (ADR) is a potent anticancer drug widely used to treat a variety of human neoplasms. However, its clinical use is hampered because of severe side effects such as cardiotoxicity and heart failure. ADR-induced cardiomyopathy (AIC) has been reported to be caused by myocardial damage and dysfunction through oxidative stress, DNA damage, and inflammatory responses. Nevertheless, the remedy for ADR cardiomyopathy is still not developed. We describe the effect of NAD⁺/NADH modulation by NAD(P)H quinone oxidoreductase 1 (NQO1) enzymatic action on AIC.